CORONA REMEDIES
|
CORONA REMEDIES Last 5 Year Cashflow Statement History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | |
|---|---|---|---|---|
| Profit Before Tax | ₹240 Cr | ₹199 Cr | ₹118 Cr | ₹111 Cr |
| Adjustment | ₹44 Cr | ₹52 Cr | ₹47 Cr | ₹23 Cr |
| Changes In working Capital | ₹-5.87 Cr | ₹-17 Cr | ₹9.32 Cr | ₹-4.92 Cr |
| Cash Flow after changes in Working Capital | ₹279 Cr | ₹234 Cr | ₹175 Cr | ₹129 Cr |
| Cash Flow from Operating Activities | ₹229 Cr | ₹190 Cr | ₹157 Cr | ₹103 Cr |
| Cash Flow from Investing Activities | ₹-256 Cr | ₹-84 Cr | ₹-267 Cr | ₹-50 Cr |
| Cash Flow from Financing Activities | ₹25 Cr | ₹-107 Cr | ₹99 Cr | ₹-45 Cr |
| Net Cash Inflow / Outflow | ₹-1.39 Cr | ₹0.06 Cr | ₹-11 Cr | ₹7.71 Cr |
| Opening Cash & Cash Equivalents | ₹3.22 Cr | ₹3.16 Cr | ₹14 Cr | ₹6.82 Cr |
| Cash & Cash Equivalent on Amalgamation / Take over / Merger | - | - | - | - |
| Cash & Cash Equivalent of Subsidiaries under liquidations | - | - | - | - |
| Translation adjustment on reserves / op cash balalces frgn subsidiaries | - | - | - | - |
| Effect of Foreign Exchange Fluctuations | - | - | ₹0.00 Cr | ₹-0.04 Cr |
| Closing Cash & Cash Equivalent | ₹1.83 Cr | ₹3.22 Cr | ₹3.16 Cr | ₹14 Cr |
Compare Cashflow Statement of peers of CORONA REMEDIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CORONA REMEDIES | ₹12,748.3 Cr | -2.9% | -0.3% | NA | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹460,696.0 Cr | 0.5% | -4% | 15.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹246,063.0 Cr | 9.1% | 18.2% | 47.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹191,515.0 Cr | 3.6% | 3.4% | 36.4% | Stock Analytics | |
| CIPLA | ₹114,554.0 Cr | -1.2% | -3.3% | -10.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,308.6 Cr | -1.4% | 2.9% | -8% | Stock Analytics | |
CORONA REMEDIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CORONA REMEDIES | -2.9% |
-0.3% |
|
| SENSEX | -0.4% |
-0.5% |
-5.8% |
You may also like the below Video Courses